Clinical trials: Sexually Transmitted Infection (STI)
HIV/AIDS
A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted
This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers.
- Trial name
- NCT03547245
- Testing
- eOD-GT8 60mer + AS01B/ DPBS sucrose/IM, DPBS Sucrose
- Where
- 2 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Neisseria Gonorrheae Infection
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
The goal of this study is to learn if a few investigational tests can correctly find the gene mutation (mutant allele gyrA 91F) that predicts ciprofloxacin resistance in clinical specimens that harbor Neisseria gonorrhoeae.
- Trial name
- MASTERMINDRING (NCT06815536)
- Testing
- Investigational Reflex Test 1, Investigational Reflex Test 2, Investigational Reflex Test 3
- Where
- 8 sites in United States
- Volunteers
- 2,627 people
- Sponsor
- Duke University
HIV Infection
Engaging Care for HIV-infected Adolescent Females.
The proposed multi-site, longitudinal study will examine the correlation of substance use, mental health disorders, and social networks to engagement in care for HIV-infected adolescent females, aged 13 years, 0 months - 23…
- Trial name
- NCT00489034
- Testing
- Quantitative Interview, Ethnographic Interview, Gender Interview
- Where
- 5 sites in United States
- Volunteers
- 178 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Study of Home-Based Resistance and Strength Training in HIV-Infected Women
Lipodystrophy is characterized by increased cardiovascular disease. Limited strategies are available to increase cardiovascular fitness in this population, particularly among women.
- Trial name
- NCT00111332
- Testing
- Progressive resistance and aerobic training
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
HIV Infection
Dipyridamole for Immune Activation in HIV
The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral load.
- Trial name
- NCT02121756
- Testing
- Dipyridamole
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sharon Riddler
Human Immunodeficiency Virus, HIV
Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection
The purpose of this study is to determine whether the current dose of nevirapine recommended in the Ontario Ministry of Health vertical transmission prevention protocol achieves therapeutic drug levels in newborn infants at high…
- Conditions
- Human Immunodeficiency Virus, HIV, Vertical Infection Transmission
- Trial name
- NCT02166502
- Where
- 2 sites in Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
HIV Infections, Hepatitis C
Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users
The purpose of this study is to test whether a six-session behavioral intervention for HIV and HCV seronegative injection drug users is effective in reducing sexual and injection risk behaviors that could lead to primary HIV and…
- Trial name
- NCT00164372
- Testing
- Peer Education Intervention
- Where
- 5 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections, HIV Wasting Syndrome
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal…
- Trial name
- NCT00002157
- Testing
- Thalidomide
- Where
- United States
- Sponsor
- Celgene Corporation
HIV Infections
Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
The purpose of this study is to determine the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with either an experimental adenoviral vector HIV vaccine of serotype 5 or 35 in HIV uninfected…
- Trial name
- NCT00472719
- Testing
- VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
- Where
- 7 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
Carotid Artery Thickness in HIV Infected and Uninfected Adults
The intima-media thickness (IMT) test is a low cost, non-invasive way to measure the thickness of the carotid artery (the large artery in the neck).
- Conditions
- HIV Infections, HIV Seronegativity, Atherosclerosis
- Trial name
- NCT00007319
- Where
- 10 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Treatment
First in Human Study of TLC-ART 101 (ACTU 2001)
This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation…
- Conditions
- Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
- Trial name
- NCT05850728
- Testing
- TLC-ART
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg…
- Trial name
- NCT00146328
- Testing
- Tipranavir
- Where
- 233 sites in United States, Argentina and 16 more
- Volunteers
- 997 people
- Sponsor
- Boehringer Ingelheim
HIV/AIDS
Motivation Matters Study
The study aims to develop and evaluate the efficacy and causal mechanisms of an interactive SMS intervention to optimize individual health and secondary HIV prevention benefits of ART in HIV-positive FSWs.
- Trial name
- MM (NCT02627365)
- Testing
- Individualized, interactive short messaging intervention
- Where
- Kenya
- Volunteers
- 119 people
- Sponsor
- University of Washington
HIV Infections
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more…
- Trial name
- NCT00447902
- Testing
- tipranavir, ritonavir
- Where
- 30 sites in United States, Argentina and 5 more
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Coronary Artery Disease
Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons
The primary purpose of this study is to evaluate the association between nonalcoholic fatty liver disease (NAFLD) by computed tomography (CT) scan and coronary artery disease (CAD) measured by the calcium (CAC) score among…
- Conditions
- HIV Infections, Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT00889577
- Where
- United States
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Cryptosporidiosis, HIV Infections
A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium
To determine the frequency of complete, marked, and partial clinical responses in patients with cryptosporidiosis treated with 6 weeks of NTZ versus 21 days of placebo.
- Trial name
- NCT00001081
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
AIDS Pneumonia, Septic Shock
Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock
Observing the Real-World Application Effectiveness of Cytokine Immune Adsorption Technology in AIDS Patients with Severe Pneumonia or septic shock.
- Trial name
- NCT06145828
- Testing
- Cytokine Adsorption
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou 8th People's Hospital
Male Circumcision, HIV Prevention
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
The purpose of this study is to evaluate the Shang Ring, a novel Chinese device for voluntary medical male circumcision, in order to improve the provision of male circumcision services for HIV prevention in Africa.
- Conditions
- Male Circumcision, HIV Prevention, HIV Infections
- Trial name
- ShangRing (NCT00993811)
- Testing
- Shang Ring circumcision
- Where
- Kenya
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
HIV Infections
Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children
CD4-IgG2 is a special man-made protein that was built to block the entrance of HIV into CD4 cells (cells of the immune system that fight infection).
- Trial name
- NCT00000876
- Testing
- CD4-IgG2
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study
The purpose of this study is to learn whether having the AMP Study antibody (called VRC01) in a person's body might help their immune system control HIV better, even without HIV medication called antiretroviral therapy or ART, if…
- Trial name
- NCT04860323
- Testing
- Analytical Treatment Interruption
- Where
- 11 sites in Botswana, Malawi and 2 more
- Volunteers
- 13 people
- Sponsor
- HIV Vaccine Trials Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.